267 results
8-K
RSPI
RespireRx Pharmaceuticals Inc.
22 Jan 24
RespireRx Pharmaceuticals Inc. Announces the Appointment of Dr. Dariusz Naziek to Its Board of Directors
8:45am
attendance. The Board may make awards to Dr. Nasiek under the Company’s 2014 Equity, Equity-Linked and Equity Derivative Incentive Plan as well
8-K
EX-99.1
RSPI
RespireRx Pharmaceuticals Inc.
22 Jan 24
RespireRx Pharmaceuticals Inc. Announces the Appointment of Dr. Dariusz Naziek to Its Board of Directors
8:45am
years is approximately US$16.5 million, most, but not all of which is expected to be eligible for the Australian R&D Tax Incentive (“RDTI”). Dronabinol
8-K
EX-10.1
RSPI
RespireRx Pharmaceuticals Inc.
11 Dec 23
Entry into a Material Definitive Agreement
8:45am
of common stock will not be issued under the Company’s 2014 Equity, Equity-Linked and Equity Derivative Incentive Plan or the Company’s 2015 Stock
8-K
EX-99.1
RSPI
RespireRx Pharmaceuticals Inc.
11 Dec 23
Entry into a Material Definitive Agreement
8:45am
Tax Incentive (“RDTI”). Dronabinol, an endocannabinoid receptor agonist, has already demonstrated significant improvement in the symptoms of OSA
8-K
EX-99.1
suu2oje
12 Oct 23
RespireRx Pharmaceuticals Inc.’s Subsidiary ResolutionRx Ltd Enters into Master Services Agreement for Dronabinol Manufacturing and Related Services
9:00am
8-K
EX-99.1
n85 hr30tnabp9smvx
9 Aug 23
RespireRx Pharmaceuticals Inc. and ResolutionRx Ltd Enter into Bilateral Agreements to Establish ResolutionRx Ltd as an Operating Company
8:52am
8-K
d7lry8
13 Jun 23
Template of Form of Phantom Stock Award Agreement
4:10pm
8-K
EX-99.1
jo6do0yv5n047qxz
13 Jun 23
Template of Form of Phantom Stock Award Agreement
4:10pm
8-K
EX-99.1
2y1 6bh8bpwbprtrvo
24 May 23
Entry into a Material Definitive Agreement
8:45am
8-K
EX-99.1
2dtf6ni
5 May 23
Regulation FD Disclosure
4:05pm